CrownBio is the only CRO with the financial commitment to expand our current collection of human primary tumorgrafts across not only tumor types with unmet clinical needs but extends it to all cancer types and all ethnicities. With over 228 established HuPrime® models fit for efficacy testing today, and an extensive genomic and proteomic data set, HuBase™ ; we can reduce your need for large efficacy studies by providing SMARTER™ model selection..
Dedicated to providing the highest quality, and most reliable xenograft animal models of all contract research outsource service providers, CrownBio is now the gold standard for efficacy testing and new model generation. Complete with guaranteed growth curves, SOC response curves, lower animal numbers per grouping, and unparalleled surgical expertise ; our ValidatedXeno™ collection is expanding an average of 4 new models per month..
HuKemia® is the world’s first and only collection of human primary hematological models available for efficacy testing and ex vivo screening. With growing collections of AML, ALL, CLL,CML, Nonhodgkin’s lymphoma, multiple myeloma, mantle cell patient samples, CrownBio extends its translational research platforms for oncology research. Complete with outcome data, these established and validated hematologic models for human leukemias mimic the clinical disease and enable the kinetics, characteristics and chemosensitivity of leukemia to be sequentially monitored in individual immunodeficient mouse model.
Due to the explosive growth in the more clinical relevant human primary tumorgraft models such as CrownBio’s HuPrime® collection, it is becoming increasingly important to be able to translate the unique profiles of each patient model and its specific tumor attributes into improving clinical trial designs. The HuBase® database, a web-based data-mining platform, is aiming to close this gap by providing expanding depth in the databases contents including; expression profiling, CNV data, mutation status, biomarker protein expression datasets, clinical histories, tumor growth and passage characteristics, etc. Stay up to date or call us for a free trial subscription.
Screen your compounds for chemotherapeutic potential against cell lines which represent closer relationship to human disease due to low passage. PrimePanel™ and PrimeLines™ cell lines come from a validated HuPrime® primary tumor models, allowing you to translate your in vitro response to the in vivo response more easily. In contrast, many ATCC cell lines do not formr tumors in vivo, and we do not know enough clinical information from the original patient. Ask about our newest screening tool today.
HumAbPHAGE™
HumAbPHAGE™ CrownBio now offers a well-established phage-based fully human IgG library for the discovery of novel therapeutics to develop a variety of mAbs against various cancer-related target proteins. This library is a naïve library made from 100% bone marrow +PB, shows diversity greater than >10^11, and antigens presented generated high quality antibodies at nM range. From antigen sequence to high value antibody in one stop including: expertise in antigen cloning, expression, purification, characterization, phage library panning, antibody cloning, expression and production.